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Abstract
Introduction: We have previously demonstrated that chondroitin sulfate glycosaminoglycans (CS-GAGs) on breast
cancer cells function as P-selectin ligands. This study was performed to identify the carrier proteoglycan (PG) and
the sulfotransferase gene involved in synthesis of the surface P-selectin-reactive CS-GAGs in human breast cancer
cells with high metastatic capacity, as well as to determine a direct role for CS-GAGs in metastatic spread.
Methods: Quantitative real-time PCR (qRT-PCR) and flow cytometry assays were used to detect the expression of
genes involved in the sulfation and presentation of chondroitin in several human breast cancer cell lines. Transient
transfection of the human breast cancer cell line MDA-MB-231 with the siRNAs for carbohydrate (chondroitin 4)
sulfotransferase-11 (CHST11) and chondroitin sulfate proteoglycan 4 (CSPG4 ) was used to investigate the
involvement of these genes in expression of surface P-selectin ligands. The expression of CSPG4 and CHST11 in 15
primary invasive breast cancer clinical specimens was assessed by qRT-PCR. The role of CS-GAGs in metastasis was
tested using the 4T1 murine mammary cell line (10 mice per group).
Results: The CHST11 gene was highly expressed in aggressive breast cancer cells but significantly less so in less
aggressive breast cancer cell lines. A positive correlation was observed between the expression levels of CHST11
and P-selectin binding to cells (P < 0.0001). Blocking the expression of CHST11 with siRNA inhibited CS-A
expression and P-selectin binding to MDA-MB-231 cells. The carrier proteoglycan CSPG4 was highly expressed on
the aggressive breast cancer cell lines and contributed to the P-selectin binding and CS-A expression. In addition,
CSPG4 and CHST11 were over-expressed in tumor-containing clinical tissue specimens compared with normal
tissues. Enzymatic removal of tumor-cell surface CS-GAGs significantly inhibited lung colonization of the 4T1 murine
mammary cell line (P = 0.0002).
Conclusions: Cell surface P-selectin binding depends on CHST11 gene expression. CSPG4 serves as a P-selectin
ligand through its CS chain and participates in P-selectin binding to the highly metastatic breast cancer cells.
Removal of CS-GAGs greatly reduces metastatic lung colonization by 4T1 cells. The data strongly indicate that CS-
GAGs and their biosynthetic pathways are promising targets for the development of anti-metastatic therapies.
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Introduction
Tumor-associated glycans play a significant role in pro-
moting aggressive and metastatic behavior of malignant
cells [1-5], participating in cell-cell and cell-extracellular
matrix interactions that promote tumor cell adhesion and
migration. Among glycans that play a critical role in stro-
mal tumor cell interactions are glycosaminoglycans
(GAGs) attached to proteoglycans (PGs). Altered produc-
tion levels of PGs and structural changes in their GAGs
are reported in many neoplastic tissues [6-10]. GAGs are
polysaccharide chains covalently attached to protein cores
that together comprise PGs [6,11] and based on the preva-
lence of GAG chains, chondroitin sulfate (CS)/dermatan
sulfate (DS) PGs (CS/DS-PGs), heparan sulfate PGs and
keratan sulfate PGs have been described [12]. Increased
production of CS/DS-GAGs is found in transformed fibro-
blasts and mammary carcinoma cells [8,13,14] and it has
been shown that these polysaccharides contribute to fibro-
sarcoma cell proliferation, adhesion and migration [15].
Several studies have disclosed the critical involvement
of P-selectin in the facilitation of blood borne metas-
tases [16-18]. P-selectin/ligand interaction often requires
sialylated and fucosylated carbohydrate such as sialyl
Lewis X and sialyl Lewis A [19]; however, P-selectin also
binds to heparan sulfate, certain sulfated glycolipids and
CS/DS-GAGs [20-23]. In previous studies we found that
CS/DS-GAGs are expressed on the cell surface of
murine and human breast cancer cell lines with high
metastatic capacity and that they play a major role in
P-selectin binding and P-selectin-mediated adhesion
of cancer cells to platelets and endothelial cells [24].
However, variation in the abundance and function of
CS/DS relative to tumor cell phenotypic properties and
P-selectin binding are not well defined. It is likely that
P-selectin binding to tumor cells and the functional
consequences of such binding are dependent on which
sulfotransferases define the relevant CS/DS and which
core proteins carry the CS polysaccharide.
CS/DS expression is controlled by many enzymes in a
complex biosynthetic pathway and this leads to consider-
able variation in structure and function. The chondroitin
backbone of CS/DS-GAGs consists of repetitive disacchar-
ide units containing D-glucuronic acid (GlcA) and N-
acetyl-D-galactosamine (GalNAc) residues, or varying pro-
portions of L-iduronic acid (IdoA) in place of GlcA
[25,26]. Major structural variability of the CS/DS chains is
due to the sulfation positions in repeating disaccharide
units by the site-specific activities of sulfotransferases that
produce the variants CS-A, CS-B (dermatan sulfate, DS),
CS-C, CS-D and CS-E [26,27]. CHST3, CHST7, CHST11,
CHST12, CHST13, CHST14 and CHST15 are the
enzymes that sulfate the GalNAc residues of chondroitin
polymers. The expression levels of these enzymes are
hypothesized to affect the production of P-selectin ligands.
CHST11 and CHST13 share specificity, as they mediate 4-
O sulfation of chondroitin [28-30]. CHST12 and CHST14
mediate mostly 4-O sulfation of DS units [30,31]. CHST3
and CHST7 share specificity for 6-O sulfation of chon-
droitin [32,33]. CHST15 transfers sulfate to the carbon-6
of an already 4-O sulfated GalNAc residue producing
oversulfated CS-E [34]. The relationship between the rela-
tive expression of these sulfotransferases with the expres-
sion of P-selectin-reactive CS/DS-GAGs has not been
reported and is addressed in this paper.
The variation, abundance and function of CS/DS-GAGs
are also affected by the expression of the PG core protein
presenting them. Syndecan-1 (SDC-1), syndecan-4 (SDC-
4), neuropilin-1 (NRP-1) and CSPG4 are considered major
pro-malignancy membrane proteins capable of carrying
CS chains [35-39]. Among these PGs, CSPG4 exclusively
carries CS chains [40,41]. CSPG4 is a human homolog of
Rat NG2, which is also known as High Molecular Weight
Melanoma Associated Antigen and Melanoma Chondroi-
tin Sulfate Proteoglycan [40,42,43]. This tumor-associated
cell surface PG potentiates cell motility and promotes
invasiveness and the metastatic potential of tumor cells in
melanoma [44-46]. CSPG4 is also linked to cancer stem
cells via signaling mechanisms [39,45]. Therefore, studying
whether this PG interacts directly with P-selectin is of par-
ticular interest.
The expression of CSPG4 in breast cancer has been
reported very recently [39]. Depending on its relative
expression levels, this PG might be a major core protein
presenting CS-GAGs on an aggressive subset of tumor
cells, interacting with P-selectin. In the current study we
investigated whether CSPG4, via its CS/DS chain can
serve as a P-selectin ligand and whether expression of spe-
cific chondroitin sulfotransferases contributes to P-selectin
interaction with cells. We further examined the involve-
ment of CS-GAG chains in lung colonization by the 4T1
mammary cell line with and without enzymatic removal of
CS-GAGs in a murine experimental metastasis model.
Our data show for the first time that P-selectin can bind
to tumor cells via CSPG4 and that CHST11 expression is
linked to P-selectin-reactive cell surface CS/DS-GAGs.
The results directly link CS/DS-GAGs to the metastatic
spread of breast cancer. These findings have significant
implications for understanding mechanisms of breast can-
cer metastasis, paving the way towards developing alterna-
tive strategies to treat and prevent metastasis.
Materials and methods
Reagents
Anti-CS-A mAb 2H6 was from Associates of Cape Cod/
Seikagaku America (Falmouth, MA, USA), anti-CSPG4
mAb 225.28 was made as described [47,48], and
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recombinant human P-selectin/Fc (human IgG) was
from R&D Systems (Minneapolis, MN, USA). Fluores-
cence-conjugated anti-human IgG, anti-mouse IgM and
chondroitinase ABC were from Sigma (St. Louis, MO,
USA). R-Phycoerythrin-conjugated polyclonal goat anti-
mouse F(ab’)2 fragment was from Dako North America,
Inc. (Carpinteria, CA, USA). DNA primers were from
Integrated DNA Technologies (IDT, Coralville, IA,
USA). Real-time PCR reagents were from Applied Bio-
systems (Foster City, CA, USA). Pre-designed siRNA
sequences were from Ambion (Austin, TX, USA) and
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
siPORT™ NeoFX™ Transfection Agent was from
Ambion. TRIzol reagent was from Invitrogen (Carlsbad,
CA, USA).
Cell lines and tissue specimens
Human breast cancer MCF7, MDA-MB-231, MDA-MB-
468 cell lines and the murine 4T1 cell line were from
ATCC (Manassas, VA, USA). Human MDA-MET cells
were selected in vivo for their bone colonizing phenotype
[49]. 4T1 cells were used within 10 passages and less
than six months after receipt. We confirmed cell line
identities by the Human Cell Line Authentication test
(Genetica DNA Laboratories, Inc. Cincinnati, OH, USA).
The melanoma cell lines M14 and M14-CSPG4, stably
transfected to express CSPG4, were used as homologous
CSPG4-non-expressing and expressing cell lines [50] and
were characterized by real-time PCR for CSPG4 expres-
sion. Cells were cultured in a base medium supplemented
with 10% heat-inactivated fetal bovine serum (Life Tech-
nologies, Carlsbad, CA, USA), 50 units/mL penicillin,
and 50 μg/mL streptomycin. Base medium for MDA-
MB-231, MDA-MET, MDA-MB-468, and 4T1 was
DMEM (Fisher Scientific, Pittsburgh, PA, USA). For
MCF7 base medium was MEM (Fisher Scientific) supple-
mented with 0.1 mM non-essential amino acids, 1 mM
sodium pyruvate, and 0.01 mg/ml insulin (Invitrogen).
For M14 and M14/CSPG4 RPMI 1640 medium (Fisher
Scientific) was used with the addition of 500 μg/ml G418
(Invitrogen). Cells are checked every six months to be
free from Mycoplasma contamination using the MycoA-
lert® Mycoplasma Detection Kit (Lonza Rockland Inc.,
Rockland, ME, USA).
De-identified frozen specimens from 15 female breast
cancer patients diagnosed with invasive ductal carcinoma
were provided by the University of Arkansas for Medical
Sciences (UAMS) Tissue Procurement Facility. Specimens
were matched for each donor to have both tumor-free and
tumor-containing breast tissues. According to the policy
of the Tissue Procurement Facility, patients signed consent
forms to donate excess specimen tissue and to allow use of
related pathological data for research purposes, which
were approved by the UAMS Institutional Review Board.
For this study, an active human tissue use protocol
approved by the UAMS Institutional Review Board was
used. In this protocol, informed consent was waived due
to the use of de-identified specimens with no link to
patient identifiers.
Total RNA isolation and qRT-PCR
Total RNA was isolated from cultured cells and tumor
tissues using TRIzol reagent, following the manufac-
turer’s instructions. The quantity and quality of the iso-
lated RNA was determined by Agilent 2100 Bioanalyzer
(Palo Alto, CA, USA). One μg of total RNA was reverse-
transcribed using random-hexamer primers with
TaqMan Reverse Transcription Reagents (Applied Bio-
systems). Reverse-transcribed RNA was amplified with
SYBR Green PCR Master Mix (Applied Biosystems) plus
0.3 μM of gene-specific upstream and downstream pri-
mers during 40 cycles on an Applied Biosystems 7500
Fast Realtime cycler. Data were analyzed by absolute and
relative quantification. In absolute quantification, data
were expressed in relation to 18S RNA, where the stan-
dard curves were generated using pooled RNA from the
samples assayed. In relative quantification, the 2 (-Delta
Delta C(T)) method was used to assess the target transcript
in a treatment group relative to that of an untreated con-
trol group using expression of an internal control (refer-
ence gene) to normalize data [51]. Expression of GAPDH
and b-actin was used as internal control. Each cycle con-
sisted of denaturation at 95°C for 15 s, and annealing and
extension at 60°C for 60 s. The primer sequences are
shown in Table 1.
Flow cytometry
Binding of the recombinant human P-selectin/Fc mole-
cule, anti-CS-A (2H6) and anti-CSPG4 (225.28) mAb to
cells was determined using flow cytometry as previously
described [24]. Briefly, cells were incubated with mAb or
P-selectin/Fc, washed and stained with FITC-conjugated
anti-mouse IgM or anti-human IgG prior to binding
detection by flow cytometry. R-phycoerythrin-conjugated
polyclonal goat anti-mouse F(ab’)2 was used as secondary
for detection of anti-CSPG4 binding.
Switching off gene expression with siRNA
Three pre-designed siRNA sequences for CHST11
(Ambion) were used (Table 1). NG2 siRNA (sc-40771)
from Santa Cruz Biotechnology, Inc. was used for inhibi-
tion of CSPG4. These sequences were transfected into
cells growing in tissue culture using the siPORT™
NeoFX™ Transfection Agent, and mRNA levels were
determined 48 hours later by real-time PCR. Expression
of GAPDH was used as reference control. Reactivity of
anti-CS-A mAb 2H6 and human recombinant P-selectin
was assessed 144 hours after siRNA transfection.
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Transfection with GAPDH siRNA (Ambion) was used as
control.
Mice and tumor models
BALB/c female mice (six to eight weeks old) were from
Harlan Laboratories (Indianapolis, IN, USA). We used
4T1 cells in an experimental metastasis model [24].
Cells were treated with chondroitinase ABC in HBSS
buffer with protease inhibitors [24], or with the buffer
and protease inhibitor alone (no chondroitinase ABC
treatment) before inoculation through the tail vein. Each
mouse (10 mice per group) received 2 × 104 4T1 cells.
Mice were sacrificed 25 days after tumor cell injection
and lungs were harvested to determine clonogenic cells
by growing cells in medium containing 6-thioguanine
[52]. Animal studies have been reviewed and approved
by the Institutional Care and Use Committee of UAMS.
Statistical analysis
For comparison of gene expression between cell lines,
the raw amount for each mRNA was normalized to the
control mRNA (18S) amount and then log transformed,
and analyzed via one-way ANOVA with Tukey’s post-
hoc procedure. For the tissue comparisons of gene
expression in patient samples, the tumor/normal expres-
sion ratios for each patient were log-transformed and
subjected to one-sample t-tests. For siRNA effects on
relative mRNA levels mean fluorescence intensities of
antibody binding were log transformed and analyzed via
ANOVA and Tukey’s post-hoc procedure. Associations
between mean fluorescence intensities of P-selectin
binding and quantities of sulfotransferase transcripts
were characterized using Pearson correlation tests on
log-transformed data. In order to check the validity of
assumptions for running Pearson’s test, Spearman corre-
lation analysis was also performed and when correlation
coefficients were similar, assumptions were considered
valid. For clonogenic assay comparisons, the number of
clonogenic lung metastases was analyzed between
groups by the Wilcoxon rank-sum test.
Results
CHST11 is overexpressed in aggressive human breast
cancer cell lines and its expression correlates with P-
selectin binding
We have shown that CS/DS-GAGs expressed on the cell
surface of MDA-MB-231 and MDA-MET human breast
cancer cells function as P-selectin ligand and that exogen-
ous CS-E efficiently inhibits P-selectin binding to cells
[24]. Among the major sulfotransferases able to sulfate the
GlaNAC residue of the chondroitin disaccharide,
CHST11, CHST12, and CHST13 are chondroitin 4-sulfo-
transferases, able to catalyze sulfation of chondroitin on
the carbon-4 position of GalNAc sugars in disaccharide
GAG units, producing primarily CS-A units (GlcAb1-
3GalNAc (4-SO4)) [28-30]. CHST14, dermatan 4-sulfo-
transferase 1 (D4ST-1), is specific for 4-O sulfation of the
GalNAc in CS-B (DS) units after dermatan sulfate epimer-
ase activity and its specificity can be shared by CHST12
[30,31]. CHST3 and CHST7 are chondroitin 6-sulfotrans-
ferases that transfer sulfate to carbon-6 position of Gal-
NAc, competing with 4-sulfotransferases for the same
substrate, producing primarily CS-C units (GlcAb1-3Gal-
NAc (6-SO4)) [32,33]. CHST15, GalNAc 4-sulfate 6-O-
sulfotransferase (GalNAc4S-6ST), transfers sulfate to the
carbon-6 of a 4-sulfated GalNAc, producing CS-E
(GlcAb1-3GalNAc (4-, 6-SO4)) [34].
Table 1 Primer and siRNA sequences used in this study
Primer Sequence
18S forward
18S reverse
5’ TTCGAACGTCTGCCCTATCAA 3’
5’ ATGGTAGGCACGGCGACTA 3’
b-actin forward
b-actin reverse
5’ GACTTCGAGCAAGAGATGGCCAC3’
5’ CAATGCCAGGGTACATGGTGGTG3’
CHST3 forward
CHST3 reverse
5’ GACTTTGTGCACAGCCTGAA 3’
5’ AGAGCTTGGGGAATCTGCTT 3’
CHST7 forward
CHST7 reverse
5’ GGGGCAATCTGTCACACTCT 3’
5’ AATTGCACAGCAGTTGTTGG 3’
CHST11 forward
CHST11 reverse
5’ TCCCTTTGGTGTGGACATCT 3’
5’ CACGTGTCTGTCACCTGGTC 3’
CHST12 forward
CHST12 reverse
5’ GCACACGTCCTTCTCTAGGC 3’
5’ AAACTCGTCGACATCGGAGT 3’
CHST13 forward
CHST13 reverse
5’ CCGGCATTTGGAAACAGAG 3’
5’ GGGTCCTGATCCAGGTCATA 3’
CHST14 forward
CHST14 reverse
5’ TCTGATCCCCCATTTATCCA 3’
5’ GGAGCAGAAAGGCACAAAAG3’
CHST15 forward
CHST15 reverse
5’ TGAGTTCACGACCAGACAGC 3’
5’ CGTACCAACAGGGGCTCTTA 3’
CSPG4 forward
CSPG4 reverse
5’ CACACAGAGGAACCCTCGAT 3’
5’ CTTCAGCGAGAGGAGCACTT 3’
ER1 forward
ER1 reverse
5’ AGGTGGGATACGAAAAGACCG 3’
5’ AAGGTTGGCAGCTCTCATGTC 3’
GAPDH forward
GAPDH reverse
5’ ACAGTCAGCCGCATCTTCTT 3’
5’ ACGACCAAATCCGTTGACTC 3’
NRP-1 forward
NRP-1 reverse
5’ CAAGGTGTTCATGAGGAAGTTCAA 3’
5’ CCGCAGCTCAGGTGTATCATAGT 3’
SDC-1 forward
SDC-1 reverse
5’ GCTCTGGGGATGACTCTGAC 3’
5’ GGTCTGCTGTGACAAGGTGA3’
SDC-4 forward
SDC-4 reverse
5’ GTCTGGCTCTGGAGATCTGG3’
5’ CACCAAGGGATGGACAACTT3’
siRNA Sequence
#31
#32
#33
UCAGUAGUUCUCGUAGACUtt
UUCUGGGUGAACUUGUUGCgg
AUCGAGUUUGUAGACUUCGta
18S, 18S ribosomal RNA; CHST3, Carbohydrate (chondroitin 6) sulfotransferase
3; CHST7, Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7; CHST11,
Carbohydrate (Chondroitin 4) Sulfotransferase 11; CHST12, Carbohydrate
(Chondroitin 4) Sulfotransferase 12; CHST13, Carbohydrate (Chondroitin 4)
Sulfotransferase 13; CHST14, Carbohydrate (N-acetylgalactosamine 4-O)
Sulfotransferase 14; CHST15, Carbohydrate (N-acetylgalactosamine 4-sulfate 6-
O) Sulfotransferase 15; CSPG4, Chondroitin Sulfate Proteoglycan 4; ER1,
Estrogen Receptor 1; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase;
NPR-1, Neuropilin-1; SDC-1, Syndecan-1; SDC-4, Syndecan-4; siRNA, short
interfering RNA.
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Quantitative real-time PCR was used to monitor the
expression levels of these genes in several human breast
cancer cell lines differing in their cancer phenotype. The
human breast cancer cell lines MCF7, MDA-MB-468,
MDA-MB-231, and MDA-MET represent increasing
aggressiveness and metastatic capacity (MCF7 < MDA-
MB-468 < MDA-MB-231 = MDA-MET). While expres-
sion of all genes was detected in these breast cancer
cells, CHST13 expression was observed to be very low
with no significant differences in expression between
cell lines (Figure 1). Among the seven sulfotransferases
tested, only CHST11 expression levels trended well with
the metastatic potential of cells, ranging from a low in
MCF7, intermediate to high in MDA-MB-468 and high
in MDA-MB-231 and MDA-MET cells (Figure 1). The
expression level of CHST11 was elevated with the
increase in metastatic potential of cells. Such a trend
was not observed with the expression levels of other
genes examined. Therefore, the data may implicate the
immediate product of CHST11 expression, CS-A, in the
metastatic behavior of these cells.
Flow cytometry analysis of the binding of the anti-CS-
A mAb 2H6, consistent with qRT-PCR data, indicates
that the expression of CS-A was lower in the least
aggressive MCF7 cell line and high in the most aggres-
sive MDA-MB-231 and MDA-MET cell lines (Figure
2A). While MDA-MB-468 showed higher expression of
CS-A than MCF7 cells, the CS-A expression in MDA-
MB-468 was not different than its expression in MDA-
MB-231 and MDA-MET. The lack of a difference in
CS-A between these three cell lines could be due to the
expression level of CHST15 that can turn the 4-sulfated
product of CHST11 to CS-E. The expression of CHST15
was significantly lower in MDA-MB-468 than in MDA-
MB-231 or MDA-MET (Figure 1) making the conver-
sion of some CS-A to CS-E much more likely in MDA-
MB-231 and MDA-MET than in MDA-MB-468. Among
the sulfotransferase genes examined, P-selectin binding
to these cells correlated the best with CHST11 expres-
sion. We performed a correlation analysis of the gene
expression levels and the mean fluorescence intensities
of P-selectin binding among all cell lines studied and
observed that only CHST11 (r = 0.85, P < 0.0001)
showed a statistically significant correlation with P-
selectin binding (Table 2). P-selectin reactivity with cell
lines was comparable to anti-CSA 2H6 binding (Figure
2A, B). These data suggest that CHST11 (a chondroitin-
4-sulfotransferase) expression in these cells is associated
with the production of P-selectin ligands.
Inhibition of CHST11 expression results in inhibition of
CS-A production and P-selectin binding
Our data indicate that CHST11 is required for P-selectin
binding. To confirm a role of 4-O sulfated structures in
P-selectin binding, the expression of CHST11 in MDA-
MB-231 cells was inhibited by siRNA. We observed that
CHST11 mRNA levels, anti-CS-A binding and P-selectin
binding were all significantly reduced upon treatment
with the three siRNAs tested (Figures 3A, B). Transfec-
tion with siRNA # 31 (Table 1) showed the highest inhi-
bitory effect on binding of anti-CS-A and recombinant
P-selectin (Figure 3B). In three independently conducted
experiments, transfection with siRNA #31 significantly
reduced the mean fluorescence intensity for anti-CS-A
(P ≤ 0.015) and P-selectin (P ≤ 0.001) binding, as com-
pared with vehicle-treated cells.
We repeated the CHST11 siRNA assay and did not
observe any effect on the CSPG4 transcript or its surface
expression as assayed by anti-CSPG4 mAb (Additional
file 1). GAPDH siRNA was used as control in siRNA
assays and reduced GAPDH mRNA by 75% in multiple
assays (data not shown). Treatment of MDA-MB-231
cells with GAPDH siRNA did not inhibit CHST11
expression (data not shown). CHST11 siRNA sequences
did not affect expression of GAPDH (data not shown).
Therefore the expression of CS-A and binding of P-
selectin to this cell line depends on the expression of
the CHST11 gene.
CSPG4 expressed on aggressive breast cancer cells
functions as a P-selectin ligand through its CS-GAGs
Because CS/DS-GAG expression and function depends on
the composition of PGs expressed, studying the nature of
the PG(s) involved in presentation of P-selectin-reactive
CS/DS is important. Such studies should help us under-
stand the functional consequences of CS/DS-GAG, PG
and P-selectin interactions and provide data that may, in
future studies, be used to manipulate the expression of the
polysaccharide by targeting the core protein(s). Several
membrane PGs, including SDC-1, SDC-4, NRP-1, and
CSPG4 can potentially present GAG chains on the surface
of tumor cells [53-55]. CSPG4 is the only cell surface PG
that is exclusively decorated with CS-GAGs [41] and
therefore, it may play a major role in forming cell surface
CS-GAGs. We compared the expression of CSPG4 in the
above described human breast cancer cell lines. The
results of qRT-PCR indicate that the less aggressive
epithelial-like cell lines MCF7 and MDA-MB-468 did not
express CSPG4, while the gene was highly expressed in the
highly aggressive mesenchymal-like cell lines MDA-MB-
231 and MDA-MET (Figure 4A). Flow cytometry analysis
further confirmed that the expression of CSPG4 was high
in aggressive cell lines MDA-MB-231 and MDA-MET
with almost no expression detected in the less aggressive
cell lines MCF7 and MDA-MB-468 (Figure 4B).
Because CSPG4 is abundant on aggressive cells, we
hypothesized that it may function as a major core protein
presenting CS-A and CS-related P-selectin ligands. We
Cooney et al. Breast Cancer Research 2011, 13:R58
http://breast-cancer-research.com/content/13/3/R58
Page 5 of 15
used CSPG4 siRNA to inhibit CSPG4 expression (Addi-
tional file 2). Inhibiting CSPG4 transcript in turn inhibited
cell surface expression of the PG (Figure 4C), and that led
to a drop in P-selectin (Figure 4D) and anti-CS-A binding
(Figure 4E). We examined the transcript levels for
CHST11 after transfection with CSPG4 siRNA (Additional
file 2). Inhibition of expression of CSPG4 did not affect
the expression of CHST11, indicating independence of
expression of these two genes. This suggests that a
decrease in CS-A after CSPG4 siRNA treatment (Figure
4E) is due to reduced expression of CSPG4 and not of
CHST11. These data suggest that CSPG4 participates in
forming P-selectin ligands on the surface of highly aggres-
sive human breast cancer cells, but obviously it is not the
only PG involved in CS-GAG presentation. Others have
reported the expression of syndecans and NRP-1 in these
breast cancer cell lines and it is known that these PGs can
present CS-GAGs [36-38,54-56]. To confirm, we further
examined the expression of SDC-1, SDC-4, NRP-1, and
CSPG4 by qRT-PCR (Table 3). The expression of SDC-1
was lower in cells with highest metastatic potential and
the expression of NRP-1, SDC-4 and CSPG4 was signifi-
cantly higher in the most aggressive cells. The abundance
of CS-A expression in MDA-MB-468 (a cell line with
intermediate aggressiveness (Figure 2A), combined with
the lack of CSPG4 expression in this cell line (Figure 4A,
B), suggest that CS chains on this cell line are probably
presented by other PGs (Table 3).
In order to confirm that P-selectin binds to CSPG4 we
used CSPG4-transfected M14 melanoma cell line
Figure 1 The expression of the chondroitin sulfotransferase genes, in the breast cancer cells used. The expression of CHST3, CHST7,
CHST11, CHST12, CHST13, CHST14, CHST15 was measured by qRT-PCR and normalized using18S. Data were analyzed by one-way ANOVA and post
hoc analysis using data from three (CHST7, CHST12, CHST13, CHST14) and four (CHST3, CHST11, CHST15) independent experiments. Means and
standard deviations are shown. Statistically significant differences and P values are shown.
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available in the lab. In prescreening of the M14 cell line,
it appeared that this cell line expresses CHST11 with
low binding of anti-CS-A 2H6 mAb and P-selectin, indi-
cating that this cell line and its transfected version are
excellent candidates for studying participation of CSPG4
and its CS GAGs in P-selectin binding. We observed
that anti-CSPG4 225.28 mAb reacted with the trans-
fected cells (M14-CSPG4) but not with mock-trans-
fected M14 cells (Figure 5A, B, C). Anti-CS-A 2H6 mAb
reacted with M14-CSPG4 but not with mock-transfected
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anti-CS-A 2H6 mAb (15 μg/ml). B) P-selectin binding to cells using recombinant P-selectin (15 μg/ml). Open histograms show binding of the
secondary antibody only (control), while filled histograms show anti-CS-A and P-selectin binding. One representative experiment out of three is
shown.
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M14 cells (Figure 5D). P-selectin also reacted with M14-
CSPG4 cells but not mock-transfected M14 cells, and
treatment of M14-CSPG4 cells with chondroitinase ABC
reduced the reactivity (Figure 5E). Pre-incubation of
cells with 225.28 did not inhibit P-selectin binding (data
not shown). These data suggest that CSPG4, via its CS
chain, serves as a P-selectin ligand on the cell surface
and that anti-CSPG4 225.28 mAb does not react with
the GAG part of CSPG4. The data further suggest that
overexpression of both CSPG4 and CHST11 genes in
tumor cells may contribute to a superior metastatic
potential.
CHST11 and CSPG4 are overexpressed in malignant
tissues of breast cancer patients
In order to establish a translational relevance, we exam-
ined the expression of CSPG4 and CHST11 in specimens
from breast cancer patients to compare the level of
expression of these genes between normal and malignant
tissues. Frozen sample-pair specimens from 15 breast
cancer patients diagnosed with invasive ductal carcinoma
were obtained from the UAMS tissue bank. In each sam-
ple pair, a tumor-containing sample was matched with
tumor-free tissue from the same donor. We observed
that these genes were overexpressed in tumor-containing
tissues versus normal tissues (Figure 6). CSPG4 and
CHST11 expression showed an increase in tumor tissue
over normal tissue in 10 out of 14 sample pairs and 8 out
of 15 sample pairs, respectively. CSPG4 was elevated 3.2-
fold (P < 0.02) in tumor tissue over normal tissue among
14 subjects, while CHST11 was elevated 1.8-fold (P =
0.034) in tumor over normal among 15 subjects (Figure
6). Gene overexpression was detected in both ER-positive
and ER-negative samples, but the majority of specimens
with increased expression of CHST11 (seven out of
eight), were HER2-neu-negative. These data suggest that
despite the stromal expression of both CHST11 and
CSPG4 genes the expression can be targeted specifically
in aggressive tumors for therapeutic purposes. In this
regard P-selectin binding to a relevant receptor on tumor
cells may have profound impact on tumor cell dissemina-
tion and understanding the detail of such interaction
may lead to development of novel anti-metastatic
approaches.
CS-GAG removal inhibits tumor metastasis
We have previously suggested a role for CS/DS-GAGs in
metastasis of the murine mammary cell line 4T1 [24]. To
directly link CS/DS-GAGs to tumor metastasis, we exam-
ined whether removal of the cell surface CS/DS-GAGs
affects metastasis of 4T1 cells in vivo. Here we demon-
strate that removing CS/DS-GAGs by treating cells with
chondroitinase ABC attenuated lung metastases in the
4T1 murine tumor model (Figure 7). Chondroitinase
treatment of cells prior to tail-vein injection significantly
reduced lung metastases (P = 0.0002). The data indicate
a significant role for tumor surface CS/DS-GAGs in
establishing lung metastases in this breast cancer model
and further support a likely role for P-selectin interaction
with CS/DS-GAG in breast cancer metastasis.
Discussion
Tumor cell dissemination by platelets leads to colonization
of cancer cells to secondary organs resulting in poor prog-
nosis and high mortality of cancer patients. P-selectin is
present on activated platelets and endothelial cells while
CS/DS-GAGs on the surface of breast cancer cells with
high metastatic potential serve as P-selectin ligands [24].
The role of P-selectin in heterotypic adhesion is a critical
component determining the efficiency of tumor cell disse-
mination [16,17]. The study of P-selectin-reactive mole-
cules on tumor cells is crucial for the assessment of
metastatic risk and the development of possible ways
of dealing with metastatic disease. Such studies are needed
to ultimately reveal the functional consequences of
P-selectin/ligand interaction in tumor progression, making
specific links between platelets and tumor metastasis.
Our results suggest the CHST11 gene as a major
player in production of such P-selectin ligands. The
results using CHST11 siRNA further suggest that among
the chondroitin sulfotransferases tested, CHST11 expres-
sion has a rate limiting role in constructing both CS-A
chains and P-selectin ligands on MDA-MB-231 cells.
This data directly links expression of the CHST11 gene
Table 2 Correlation coefficients between P-selectin
binding to cells and the expression of the
sulfotransferases studied
Sulfotransferase gene Pearson r number P value (two-tailed)
CHST3 0.25 16 0.36
CHST7 0.45 12 0.14
CHST11 0.85 16 <0.0001
CHST12 0.32 12 0.30
CHST13 -0.37 12 0.24
CHST14 0.20 12 0.52
CHST15 0.29 16 0.31
Gene expression was measured by qRT-PCR and normalized using 18S
transcript. Mean Fluorescence Intensities of P-selectin binding to cells was
assayed by flow cytometry. Cell lines were MCF7, MDA-MB-468, MDA-MB-231,
and MDA-MET. Each assay was repeated independently 3 times per cell line
for CHST7, CHST12, CHST13 and CHST14 and 4 times per cell line for CHST3,
CHST11, CHST15. Then the data were log transformed and subjected to
correlation analysis using both Pearson (parametric) and Spearman
(nonparametric) correlation tests in order to check validity of assumptions.
Correlation coefficients were similar, assumptions were considered valid, and
the Pearson coefficient was reported. CHST3, Carbohydrate (chondroitin 6)
sulfotransferase 3; CHST7, Carbohydrate (N-acetylglucosamine 6-O)
sulfotransferase 7; CHST11, Carbohydrate (Chondroitin 4) Sulfotransferase 11;
CHST12, Carbohydrate (Chondroitin 4) Sulfotransferase 12; CHST13;
Carbohydrate (Chondroitin 4) Sulfotransferase 13; CHST14, Carbohydrate
(N-acetylgalactosamine 4-O) Sulfotransferase 14; CHST15, Carbohydrate
(N-acetylgalactosamine 4-sulfate 6-O) Sulfotransferase 15.
Cooney et al. Breast Cancer Research 2011, 13:R58
http://breast-cancer-research.com/content/13/3/R58
Page 8 of 15
to P-selectin-reactive GAGs on this cell line and has sig-
nificant implications for further functional studies. CS-A
is an immediate product of CHST11 expression and is
considered a precursor in forming CS-E units [57]. P-
selectin has been shown to bind to CS-E [23]. We have
also shown that exogenous CS-E inhibits P-selectin
binding to cancer cells [24]. While we do not rule out
participation of CS-E in P-selectin binding, our data do
not support CS-E as the P-selectin reactive GAG unit
on these cells. The combined high expression of these
Figure 3 Inhibition of CHST11 expression and P-selectin binding to MDA-MB-231 cells by CHST11 siRNA. MDA-MB-231 cells were treated
with three different siRNAs for the CHST11 gene. RNA was harvested after 48 hours and gene expression was assayed at the mRNA level (A).
GAPDH was used as the house keeping gene to normalize mRNA-based expression data using the delta delta CT method. CHST11 mRNA levels
are shown relative to mRNA level in cells treated with transfection agent only (vehicle). Data were log transformed and subjected to one way
ANOVA with post-hocTukey’s analysis. B) Binding of anti-CS-A (2H6 mAb) (top) and P-selectin (bottom) was tested at Day 6 post siRNA
transfection. Binding of secondary antibodies only serves as control. Binding of anti-CS-A 2H6 mAb and recombinant human P-selectin to
vehicle-treated and siRNA-treated MDA-MB-231 cells with the three siRNAs is shown. Mean fluorescent intensities of three independent
experiments were log transformed and analyzed by ANOVA and post-hoc comparison. Treatment with CHST11 siRNA #31 significantly reduced
mean fluorescent intensities for anti-CS-A 2H6 mAb (P ≤ 0.015) and P-selectin (P ≤ 0.001) binding, as compared with vehicle-treated cells.
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two genes may associate with P-selectin-reactive glycans
and aggressiveness. This possibility should be investi-
gated in future studies. However, the data indicate that
the expression of the CHST11 gene in tumor cells is
associated with synthesis of P-selectin ligands and a
metastatic phenotype. Others have suggested a role for
CS-A in tumor progression and metastasis in a mela-
noma model [46]. However, our data suggest that sur-
face presentation of CS-A may be required but is not
sufficient for a metastatic phenotype to occur. Besides
its role in constructing CS-A, CHST11 also plays a role
in chain elongation and production of more CS [57].
Chain elongation activity of CHST11 with a fine balance
in the expression of other enzymes might be needed for
constructing conformational epitopes. Thus, CHST11
activity may lead to larger CS polymers with multiple
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Figure 4 The expression of CSPG4 in aggressive breast cancer cell lines contributes to P-selectin binding. A) CSPG4 mRNA was
measured by qRT-PCR and normalized to 18S values and log transformed. Means and standard deviations are shown. Comparisons were made
by ANOVA and post-hoc analysis. B) Cell surface expression of CSPG4 was examined in the indicated breast cancer cell lines by flow cytometry
using anti-CSPG4 225.28 mAb (10 μg/ml). Open histogram shows binding of the secondary antibody only, while filled histogram shows anti-
CSPG4 225.28 mAb binding. One representative experiment out of three is shown. C) Expression of CSPG4 was inhibited by transient
transfection of MDA-MB-231 cells with CSPG4 siRNA that led to a decrease in the binding of P-selectin (D) and anti-CS-A (E) to transfected cells
In C, D and E the filled histograms show the binding of secondary antibodies only (control), the open histograms with solid lines show binding
to vehicle-treated cells while the open histograms with dotted lines show binding to the siRNA-transfected cells.
Table 3 Ratio of mRNA for some PG genes to 18S RNA
Antigen MCF7 MDA-MB-468 MDA-MB-231 MDA-MET
CSPG4 0.02 (± 0.006) 0.03 (± 0.02) 2.43 (± 0.56) 2.15 (± 0.8)
NRP-1 0.96 (± 0.10) 1.00 (± 0.08) 1.55 (± 0.20) 1.96 (± 0.07)
SDC-1* 0.45 (± 0.07) 2.09 (± 0.18) 0.22 (± 0.03) 0.13 (± 0.04)
SDC-4** 0.58 (± 0.08) 0.86 (± 0.07) 1.50 (± 0.30) 1.90 (± 0.11)
ER1 4.84 (± 0.59) 0.12 (± 0.03) 0.14 (± 0.03) 0.11 (± 0.02)
Gene expression was measured by qRT-PCR assays, repeated 3 times for each
gene and each cell line and averages (± standard deviations) are shown. One-
way ANOVA with Tukey’s post-hoc procedure on log-transformed data was
used for statistical analysis as described in Materials and Methods. Bold
entries are statistically different (at P < 0.05) than non-bold entries in each
row. *The expression of SDC-1 in MDA-MB-468 cells is significantly higher
than that in MDA-MB-231 and MDA-MET cells. **The expression of SDC-4 in
MDA-MB-468 cells is significantly less than that in MDA-MB-231 and MDA-MET
cells. The expression of ER1 was used as a control knowing that MCF7 is ER-
positive and the other three cell lines are ER-negative. CSPG4, Chondroitin
Sulfate Proteoglycan 4; ER1, Estrogen Receptor 1; NPR-1: Neuropilin-1; SDC-1,
Syndecan-1; SDC-4, Syndecan-4.
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sequences embedded with distinct sulfation patterns
resulted from activity of multiple sulfotransferases, lead-
ing to the production of conformational epitopes or
highly concentrated sequences with specific reactivities.
Thereby, the expression of CHST11 may correlate better
with the tumor cells’ aggressive phenotype than does
the prevalence of any particular CS isomers.
Interestingly, our current results implicate CSPG4 in
the presentation of CS moieties as P-selectin ligands.
CSPG4 exclusively presents CS-GAGs, and the data
described here suggest that these structures interact
with P-selectin and, therefore, may contribute to distant
metastasis of tumor cells. Our data indicate that P-selec-
tin binds to CSPG4 through CS-GAGs and that CSPG4
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Figure 5 Expression of CSPG4 leads to an increase in CS-A expression and P-selectin binding. A) Secondary Ab binding (control) to
CSPG-4-transfected M14 (M14-CSPG4). Anti-CSPG4 (mAb 225.28) binding to M14-mock-transfected is minimal (B), while the binding is high to
CSPG4-transfected cells (C). D) Overlay histogram of 2H6 mAb (anti-CS-A) binding to the M14-mock-transfected (filled histogram) and M14-
CSPG4 cell line (open histogram). E) P-selectin binds to M14-CSPG4 (open histogram, solid line) and not to M14-mock-transfected (filled
histogram). Binding of P-selectin to M14-CSPG4 is reduced after treatment with chondroitinase ABC (dotted line shifted to the left). The
experiment was repeated three times and one representative is shown.
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is involved in P-selectin binding to CSPG4-expressing
breast cancer cells. However, other PGs may also parti-
cipate in P-selectin binding as expression of SDC-4 and
NRP-1 is also higher in MDA-MB-231 and MDA-MET.
Lack of expression of CSPG4 in MDA-MB-468 further
suggests that anti-CS-A and P-selectin binding to these
cells is probably due to expression of other PGs and not
CSPG4. However, because of the role of CSPG4 in sig-
naling and tumor phenotype, we speculate that its inter-
action with P-selectin may lead to an exclusive tumor
cell activation and consequently survival in circulation.
Therefore, concerted upregulation of CSPG4 and
CHST11 may induce expression of a unique molecular
entity that may increase the metastatic capabilities of
tumor cells. More studies are needed to understand the
consequences of P-selectin binding to CS-GAGs of mul-
tiple PGs and to reveal how and at what stage of the
metastatic cascade the CS-GAGs and their carrier pro-
teins contribute to metastasis.
We have shown glycan interactions with P-selectin and
the significance of P-selectin binding in metastasis of a
murine mammary cell line [24,52]. Our previous findings
support the concept that CS chains promote survival in
the circulation and tumor cell extravasation via P-selectin-
mediated binding to platelets and endothelial cells. In the
current study, the significance of the cell surface expres-
sion of CS-GAGs in a breast cancer model is established.
The data demonstrate that enzymatic removal of the CS
chains significantly attenuated formation of lung metas-
tases in a highly metastatic mammary cell line. Others
have shown that P-selectin ligands are critical components
of heterotypic adhesion, determining the efficiency of
tumor cell dissemination [16,17]. Sugahara’s group
demonstrated that highly sulfated CS-GAGs, in particular
CS-E, are involved in metastasis of murine lung carcinoma
and osteosarcoma cells [58,59]. However, our data suggest
a role for 4-O sulfation of chondroitin in the metastatic
phenotype. Moreover, the data suggest that the presence
of CS/DS-GAGs may not be sufficient for a phenotype
with high metastatic capacity to occur. The data empha-
size a combination of the polysaccharide and a core pro-
tein as a pro-metastatic entity. Future studies are needed
to understand the contribution of each PG in P-selectin
mediated tumor cell behavior.
We further showed that the expression of CHST11
and CSPG4 is elevated in tumor tissues from breast
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Foldchange(cancer/normal)
Observed value Mean(95%CI)
CSPG4
CHST11
Figure 6 Expression of the CSPG4 and the CHST11 genes was detected in breast tissue samples. mRNA expression was quantified by
absolute quantification and the ratio of mRNA to 18S mRNA was calculated. The fold change in tumor sample compared to normal tissue
sample in each subject was calculated and plotted. Circles denote individual observations, while squares with error bars represent group means
with their 95% confidence intervals (CIs). CSPG4 and CHST11 were elevated 3.2 (P < 0.02) and 1.8 (P = 0.034) fold, respectively in tumor-
containing samples over normal samples.
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cancer patients. Consistent with our data, CHST11
expression has been shown to be greater in human
breast carcinoma compared to normal breast tissue [60]
and in malignant plasma cells from myeloma patients
compared to normal bone-marrow plasma cells [61].
The current research should lead to future studies of
functional relationships between CS and tumor progres-
sion. Existing knowledge and further mechanistic studies
might suggest CS-GAGs and their presenting PGs as tar-
gets for antimetastatic therapies. In support of work done
in melanoma [62] and recent studies in breast cancer [39],
the studies outlined here strongly suggest that CSPG4 can
be an available target for immunotherapy of breast cancer.
However, in order to efficiently block tumor cell dissemi-
nation by interrupting P-selectin/CS interaction, targeting
any single PG does not seem enough as other PGs can
probably compensate and support metastatic processes. In
this regard, global targeting of specific CS isomers may be
a particularly effective approach.
Breast cancer cell surface is decorated with CS-GAGs
and due to tumor-specific expression patterns of chon-
droitin sulfotransferases and PGs, the composition and
binding specificity of these polysaccharides differ from
those of normal tissues. Therefore, these molecules and
their interaction with P-selectin should be considered as
viable targets for the development of novel therapeutic
strategies.
Conclusions
This study demonstrates the significance of CS-GAGs in
the lung colonization of an aggressive murine mammary
cell line. The study reveals that CSPG4 can serve as a P-
selectin ligand through its CS chain and that the expres-
sion of the CHST11 gene controls P-selectin reactive
CS-GAGs formation. The data suggest that CS-GAGs,
their biosynthetic pathway, or the core protein carrying
them can be potential-targets for the development of
therapeutic strategies for treatment of aggressive breast
tumors. The knowledge and perspective gained from
this line of research together with further mechanistic
studies may pave the road to target CS-GAGs, their car-
rier PGs and their interaction with P-selectin as novel
antimetastatic therapies.
Additional material
Additional file 1: Supplemental Figure S1. Transient transfection of
MDA-MB-231 cells with CHST11 siRNA inhibits CHST11 expression (A),
anti-CS-A (C) and P-selectin (D) binding with no effect on CSPG4 mRNA
(B) or the surface expression of the PG (E).
Additional file 2: Supplemental Figure S2. Fold change in the
expression of CHST11 and CSPG4 mRNA after transient transfection with
CSPG4 siRNA. The expression of genes was measured 48 hours post
transfection by qRT-PCR. Fold change is calculated based on the
expression of genes in vehicle-treated cells. GAPDH message was used
to normalize the data. Transfection with a scrambled siRNA was used as
additional control. **, significantly different than expression in either cells
only or cells transfected with scrambled siRNA at P < 0.01.
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